Former executive at Thermo Fisher Scientific Inc
- Recent developments in cell and gene therapy market, focusing on outsourcing trends to CDMOs (contract development and manufacturing organisations)
- Potential disruptions to supply chain following coronavirus restrictions and inefficiencies to operations
- Competitive positioning of large vendors across product offerings
- Industry M&A dynamics and growth expectations, highlighting potential gaps in large players’ offerings and Danaher’s (NYSE: DHR) outlook after August 2021 acquisition of Aldevron
Gain access to Premium Content
Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.